Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5
27 Février 2007 - 2:00PM
PR Newswire (US)
WESTMINSTER, Colo., Feb. 27 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), today announced that it will
report its fourth quarter and 2006 financial results on Monday,
March 5, 2007, before the open of the U.S. financial markets. Paul
L. Berns, President and Chief Executive Officer, and other members
of Allos' senior management will provide a company update and
review 2006 results via webcast and conference call on Monday,
March 5, 2007 at 11:00 AM ET. The dial in number for U.S. residents
to participate is 877-407-8031. International callers should dial
201-689-8031. Participants should reference the Allos Therapeutics
conference call. An audio replay of the conference call will be
available from 5 PM ET on Monday, March 5, 2007, until 11:59 PM ET
on Thursday, March 15, 2007. To access the replay, please dial
877-660- 6853 (domestic) or 201-612-7415 (international); Replay
pass codes (both required for playback): account # 286; conference
ID # 231653. The webcast of this call will be available from the
homepage and the investors/media section of the company's web site,
http://www.allos.com/ and will be archived for 30 days. About Allos
Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The company has two product candidates in late-stage
clinical development: EFAPROXYN(TM) (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in
women with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The company is also
evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1
trial in patients with advanced solid tumors. For additional
information, please visit the company's website at
http://www.allos.com/. Safe Harbor Statement The 2006 fourth
quarter results press release and conference call will contain
forward-looking statements that involve significant risks and
uncertainties, including those contained in the "Risk Factors"
section of the company's Annual Report on Form 10-K for the year
ended December 31, 2005 and in the company's other periodic reports
and filings with the Securities and Exchange Commission. Allos is
providing the information contained in the press release and
conference call as of the date of the release and does not
undertake any obligation to update any forward- looking statements
as a result of new information, future events or otherwise. The
company cautions investors not to place undue reliance on the
forward- looking statements contained in the press release or the
conference call. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman, Manager, Corporate Communications of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics (MM)